使用贝叶斯方法推断生存数据:一种案例研究,利用多发性骨髓瘤中纤维细胞治疗的外部数据
Stephen Palmer1, Yi Lin2, Thomas G Martin3
1Center for Health Economics, University of York, York, UK.
Oncology and therapy
|June 4, 2023
概括
使用外部数据的灵活贝叶斯方法改善了多发性骨髓瘤中ciltacabtagene autoleucel (cilta-cel) 的长期生存预测. 与传统模型相比,这种方法减少了不确定性,提供了更可靠的整体存活率估计.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 卫生技术评估 卫生技术评估
背景情况:
- 准确的长期总生存率 (OS) 估计对于瘤健康技术评估至关重要.
- 传统的推断方法往往会给长期的操作系统预测带来很大的不确定性.
- Ciltacabtagene autoleucel (cilta-cel) 是一种用于多发性骨髓瘤的仿真抗原受体T细胞疗法.
研究的目的:
- 展示一个灵活的贝叶斯方法来减少长期OS外推的不确定性.
- 利用外部的长期生存数据来根据短期临床试验数据进行预测.
- 为了比较贝叶斯模型的性能与使用ciltacabtagene autoleucel数据的传统方法.
主要方法:
- 来自CARTITUDE-1试验 (NCT03548207) 对ciltacabtagene autoleucel.的12个月的OS数据进行外推.
- 采用了传统的生存模型 (未知参数分布) 和贝叶斯生存模型 (来自LEGEND-2研究的信息先验,NCT03090659).
- 通过将12个月的预测与观察到的28个月的CARTITUDE-1数据进行比较,验证了外推.
主要成果:
- 传统的不知情模型产生了高度可变的OS推断.
- 由48个月的LEGEND-2数据提供信息的贝叶斯模型产生了持续更窄的投影范围.
- 与大多数传统模型相比,知情贝叶斯模型在外推和观察的28个月的操作系统数据之间显示出较小的差异.
结论:
- 被告知的贝叶斯生存模型有效地减少了长期OS预测中的变化.
- 这些模型产生了更狭窄,更合理的OS预测,这些预测与观察到的数据保持一致.
- 贝叶斯方法提供了一个更可靠的方法来从瘤学中短期临床试验数据中推断长期存活率.
相关概念视频
01:24Kaplan-Meier Approach
197
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
197
01:21Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
01:20Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
01:15Assumptions of Survival Analysis
160
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
160
01:20Actuarial Approach
101
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
101
01:09Censoring Survival Data
152
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
152